Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Open, laparoscopic, and robotic ventral and inguinal hernia repair. Main billing specialty: general surgery.
Medicare fee-for-service hernia repair cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (255 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 233 | 17,286−1.1%/yr | −1.1%/yr | 5.50.9× | 15% | 19,300 in 2030+1.8%/yr |
| Florida | 187 | 13,939−2.8%/yr | −2.8%/yr | 6.71.1× | 7% | 15,700 in 2030+2%/yr |
| Texas | 166 | 12,981−3%/yr | −3%/yr | 6.41.1× | 6% | 14,900 in 2030+2.3%/yr |
| New York | 131 | 10,502−1.8%/yr | −1.8%/yr | 6.11.0× | 7% | 11,800 in 2030+1.9%/yr |
| Pennsylvania | 114 | 8,075−2.5%/yr | −2.5%/yr | 6.31.0× | 4% | 8,470 in 2030+0.8%/yr |
| Illinois | 88 | 7,166−3.6%/yr | −3.6%/yr | 5.50.9× | 7% | 8,010 in 2030+1.9%/yr |
| Ohio | 75 | 6,844−3.3%/yr | −3.3%/yr | 6.61.1× | 5% | 7,430 in 2030+1.4%/yr |
| Virginia | 89 | 6,010−2.5%/yr | −2.5%/yr | 6.01.0× | 2% | 6,760 in 2030+2%/yr |
| New Jersey | 76 | 5,785−0.6%/yr | −0.6%/yr | 5.81.0× | 4% | 6,020 in 2030+0.7%/yr |
| North Carolina | 69 | 5,606−5%/yr | −5%/yr | 6.01.0× | 6% | 6,060 in 2030+1.3%/yr |
| Arizona | 84 | 5,543−0.6%/yr | −0.6%/yr | 7.91.3× | 12% | 6,180 in 2030+1.8%/yr |
| Georgia | 62 | 5,304−4.6%/yr | −4.6%/yr | 6.61.1× | 1% | 5,880 in 2030+1.7%/yr |
| Massachusetts | 66 | 5,037−2.7%/yr | −2.7%/yr | 5.60.9× | 1% | 5,860 in 2030+2.6%/yr |
| Michigan | 38 | 4,810−7%/yr | −7%/yr | 6.11.0× | 4% | 4,960 in 2030+0.5%/yr |
| Maryland | 60 | 4,436+0.2%/yr | +0.2%/yr | 5.20.8× | 9% | 5,200 in 2030+2.7%/yr |
| Washington | 50 | 4,184−4.3%/yr | −4.3%/yr | 5.81.0× | 11% | 4,250 in 2030+0.3%/yr |
| Missouri | 51 | 4,103−3.2%/yr | −3.2%/yr | 7.01.2× | 3% | 5,000 in 2030+3.4%/yr |
| Indiana | 39 | 4,058−4.6%/yr | −4.6%/yr | 6.11.0× | 11% | 4,490 in 2030+1.7%/yr |
| South Carolina | 55 | 3,960−2.1%/yr | −2.1%/yr | 6.11.0× | 5% | 4,850 in 2030+3.4%/yr |
| Tennessee | 52 | 3,956−4.3%/yr | −4.3%/yr | 6.01.0× | 9% | 4,290 in 2030+1.4%/yr |
| Colorado | 52 | 3,413−0.2%/yr | −0.2%/yr | 7.41.2× | 11% | 3,950 in 2030+2.5%/yr |
| Wisconsin | 34 | 3,364−3.4%/yr | −3.4%/yr | 6.41.0× | 3% | 3,770 in 2030+1.9%/yr |
| Alabama | 23 | 2,616−6.7%/yr | −6.7%/yr | 6.41.0× | 5% | 2,470 in 2030−1%/yr |
| Minnesota | 18 | 2,581−3.2%/yr | −3.2%/yr | 6.11.0× | 8% | 3,830 in 2030+6.8%/yr |
| Oklahoma | 30 | 2,570−3.5%/yr | −3.5%/yr | 5.60.9× | 0% | 2,900 in 2030+2.1%/yr |
| Kentucky | 20 | 2,512−6.9%/yr | −6.9%/yr | 5.81.0× | 1% | 2,530 in 2030+0.1%/yr |
| Oregon | 23 | 2,486−2.6%/yr | −2.6%/yr | 6.31.0× | 10% | 3,210 in 2030+4.4%/yr |
| Louisiana | 21 | 2,378−5.5%/yr | −5.5%/yr | 6.21.0× | 3% | 2,210 in 2030−1.2%/yr |
| Kansas | 27 | 2,322−2.7%/yr | −2.7%/yr | 6.01.0× | 12% | 2,400 in 2030+0.5%/yr |
| Mississippi | 23 | 2,013−6.1%/yr | −6.1%/yr | 5.60.9× | 2% | 2,210 in 2030+1.6%/yr |
| Arkansas | 21 | 2,007−3.9%/yr | −3.9%/yr | 5.60.9× | 7% | 2,270 in 2030+2.1%/yr |
| Connecticut | 25 | 1,918−2.5%/yr | −2.5%/yr | 6.21.0× | 0% | 2,470 in 2030+4.3%/yr |
| Utah | 25 | 1,792+0.1%/yr | +0.1%/yr | 8.71.4× | 7% | 1,820 in 2030+0.3%/yr |
| Iowa | 22 | 1,777−4.7%/yr | −4.7%/yr | 4.20.7× | 7% | 1,970 in 2030+1.7%/yr |
| Nevada | 24 | 1,609−1.2%/yr | −1.2%/yr | 6.01.0× | 0% | 1,850 in 2030+2.4%/yr |
| Nebraska | 17 | 1,596−3.4%/yr | −3.4%/yr | 6.41.0× | 14% | 1,920 in 2030+3.1%/yr |
| New Hampshire | 13 | 1,120−0.6%/yr | −0.6%/yr | 5.20.8× | 2% | 1,720 in 2030+7.5%/yr |
| Idaho | 14 | 1,085−3%/yr | −3%/yr | 5.60.9× | 1% | 1,430 in 2030+4.7%/yr |
| Delaware | 10 | 997−4.5%/yr | −4.5%/yr | 6.01.0× | 5% | 1,250 in 2030+3.9%/yr |
| New Mexico | 11 | 986−2.8%/yr | −2.8%/yr | 4.50.7× | 1% | 970 in 2030−0.2%/yr |
| Montana | 14 | 967−2.5%/yr | −2.5%/yr | 5.30.9× | 2% | 1,050 in 2030+1.3%/yr |
| West Virginia | 8 | 821−8.3%/yr | −8.3%/yr | 4.20.7× | 0% | 620 in 2030−4.5%/yr |
| South Dakota | 6 | 763−5.7%/yr | −5.7%/yr | 6.11.0× | 0% | 930 in 2030+3.3%/yr |
| Maine | 2 | 755−6.9%/yr | −6.9%/yr | 5.10.8× | 0% | 940 in 2030+3.8%/yr |
| North Dakota | 7 | 627−1.4%/yr | −1.4%/yr | 6.61.1× | 0% | 580 in 2030−1.4%/yr |
| Alaska | 8 | 607+4.7%/yr | +4.7%/yr | 5.10.8× | 8% | 750 in 2030+3.5%/yr |
| District of Columbia | 4 | 587−0.4%/yr | −0.4%/yr | 9.81.6× | 12% | 630 in 2030+1.3%/yr |
| Wyoming | 5 | 507+0.6%/yr | +0.6%/yr | 4.80.8× | 0% | 660 in 2030+4.6%/yr |
| Rhode Island | 6 | 457−5.4%/yr | −5.4%/yr | 5.40.9× | 0% | 350 in 2030−4.5%/yr |
| Vermont | 6 | 439+0.5%/yr | +0.5%/yr | 4.00.7× | 0% | 760 in 2030+9.5%/yr |
| Hawaii | 2 | 372−1.1%/yr | −1.1%/yr | 3.10.5× | 4% | 390 in 2030+1%/yr |
Professional codes (what the surgeon bills): CPT 49505, 49650, 49651, 49560, 49561, 49565, 49566, 49570, 49572, 49585, 49587, 49590, 49652, 49653, 49654, 49655, 49656, 49657, 49591, 49592, 49593, 49594, 49595, 49596, 49613, 49614, 49615, 49616, 49617, 49618, 49621, 49622; the hospital bills MS-DRG 353, 354, 355.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 90 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 33 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 18 |
| BD | 12 |
| Johnson & Johnson MedTech | 8 |
| Aziyo Biologics | 4 |
| Cook Biotech | 4 |
| Deep Blue Medical Advances | 4 |
| Tela Bio | 4 |
| Alafair Biosciences | 3 |
| Aroa Biosurgery | 3 |
| Xiros | 3 |
| Acell | 2 |
| Baxter | 2 |
Product codes: FTL (mesh, surgical, polymeric), FTM (mesh, surgical), OWT (mesh, surgical, absorbable, abdominal hernia). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 17% of the cases CMS names in California; 139 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Cholecystectomy & appendectomy | 2,560 | 131,995−5.4%/yr | −5.4%/yr | 140,500 in 2030+1%/yr |
| Colorectal resection | 232 | 52,254−5.2%/yr | −5.2%/yr | 53,600 in 2030+0.4%/yr |
| Antireflux & hiatal hernia surgery | 375 | 23,396−1.8%/yr | −1.8%/yr | 28,800 in 2030+3.5%/yr |
| Breast reconstruction | 66 | 13,660−6.4%/yr | −6.4%/yr | 17,400 in 2030+4.1%/yr |
| Bariatric surgery | 15 | 4,952−17%/yr | −17%/yr | 3,750 in 2030−4.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 13 companies reported engagement with surgeons in the covered states worth $4.8M in consulting, speaking, meals and travel tied to these products, about $2,063 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.